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Expression of resistance. The BioscreenR  was used to analyze the growth curves of 
R.equi RE-S7B non-exposed and exposed to 8 mg/l vancomycin (without prior 
exposure to vancomycin and with pre-exposure to vancomyin) over 2 days at 30 ̊C. 
OD600 was measured every 30 min. Experiments were done in triplicate. In addition, 
minimum inhibitory concentration (MIC) was also tested by Etest® on RE-S7B pre-
exposed to increasing concentrations of vancomyin. 
Whole genome sequencing. RE-S7B was sequenced using Illumina paired-end (PE) 
technology (500bp library).  De novo assembly was done using Geneious v6.3,  van-




Results and Conclusions 
RE-S7B harbors a vanA-like operon consisting of a vanHAX cluster and a two-component regulatory system, displaying  60-63% and 39-41% 
amino acid identity to the enterococcal vanA genes, respectively (FIG. 3). The gene organization is unique and includes a novel transposase type 
and additional putative open reading frames. The proposed name for this novel operon is vanRE. 
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Vancomycin and teicoplanin are last  resort  glycopeptide  drugs for treatment of 
MRSA  and enterococcal infections. They inhibit cell wall formation by binding to the 
D-Ala-D-Ala terminal residues of peptidoglycan precursors.  Resistance is due to 
synthesis of low affinity precursors that terminate with either D-Ala-D-Lac or D-Ala-D-
Ser (1). VanA-type is the most common glycopeptide resistance in enterococci and is 
characterized by inducible high-level resistance to both vancomycin and teicoplanin 
(2).  
Rhodococcus equi is Gram-positive,soil coco-bacillus that causes severe 
bronchopneumonia in horses. It can also cause fatal infections in 
immunocompromised humans (3).VanR has been reported in  human clinical R.equi 
isolates (4), however the resistance mechanism is unknown.  
RE-S7B had a vancomycin MIC >32µg/mL and teicoplanin MIC = 8µg/mL. At sub inhibitory  concentration of vancomycin, vancomycin exposed cells  
resume growth faster than  non-exposed cells (FIG.1). The MIC increased proportionally when exposed to higher vancomycin concentrations (FIG.2). 
Figure 2: Vancomycin MIC values of RE-S7B recovered from BHI agar   plates 
with no vancomycin (A), 8 mg/l of vancomycin (B) and 20 mg/l of vancomycin 
(C).   
Figure 1: Glycopeptide resistance expression of RE-S7B. 
Figure 3: Organization of vanA in E. faecium , vanARE in RE-S7B, van-like 
clusters in Amycolatopsis spp. ATCC 39116 (NCBI BLAST) and Frankia spp. 
EAN1pec (NCBI BLAST). Arrows indicate direction of transcription. Percentages 
below and above the arrows indicate GC content and Nucleotide  identity of the 
corresponding gene to vanARE operon in RE-S7B.     
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RE-S7B harbors a unique van operon  
OBJECTIVE: To elucidate the mechanism of  glycopeptide 
resistance in a vancomycin resistant  Rhodococcus equi  isolated 
from Danish soil. 
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